GlaxoSmithKline plc CEDEAR (GSK)
BCBA
20,910.00
+280.00 (+1.36%)
Real-time Data
02:00 PM
Day's Range
20,450.0020,940.00
52 wk Range
12,975.0022,760.00
Financial Statements - GSK - GlaxoSmithKline plc CEDEAR
Revenue
32.66B▼ 99.9%
Net Income
6.28B▼ 99.9%Net Margin 19.3%
EBITDA
10.70B▼ 99.9%
Free Cash Flow
4.75B▼ 99.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 32.66B | 61.97T | 30.32B | 29.32B | 24.69B | 24.35B |
| Cost of Goods | 9.01B | 17.87T | 8.56B | 9.55B | 8.16B | 7.92B |
| Gross Profit | 23.65B | 44.10T | 21.76B | 19.77B | 16.53B | 16.42B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 8.33B | 10.94T | 7.34B | 6.72B | 4.87B | 4.57B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 7.40B | 6.86T | 6.06B | 5.62B | 3.59B | 5.17B |
| Income Tax | 1.11B | 1.03T | 756M | 707M | 83M | 67M |
| Net Income | 6.28B | 5.82T | 5.30B | 15.62B | 5.09B | 6.38B |
| EPS Basic | 0.7055 | 0.316 | 0.608 | 1.857 | 0.5475 | 0.721875 |
| EPS Diluted | 0.694 | 0.311 | 0.5995 | 1.831 | 0.54125 | 0.713125 |
| Basic Shares Outstanding | 8.10B | 16.10T | 6.05M | 6.16M | 6.13M | 6.09M |
| Diluted Shares Outstanding | 8.10B | 16.10T | 6.05M | 6.16M | 6.13M | 6.09M |
| Ebit | 8.08B | 8.13T | 6.78B | 6.45B | 4.36B | 6.01B |
| Ebitda | 10.70B | 16.05T | 9.62B | 8.87B | 7.04B | 6.65B |
| Net Income Continuous Operations | 6.28B | 5.82T | 5.30B | 4.92B | 3.51B | 5.10B |
| Minority Interests | -573M | -376M | -380M | -665M | -711M | -639M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
